GLPwatch
Xultophy for Fertility ("Ozempic babies")
liraglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCXultophy (liraglutide) is not FDA-approved for improving fertility. Research includes small studies and animal models suggesting potential effects on reproductive function, but these findings are not conclusive for human use.
AI summary of the sources below.
| Drug | Xultophy (liraglutide) |
|---|---|
| Condition | Fertility ("Ozempic babies") |
| Approval status | Investigational / off-label |
| Research papers | 9 |
Xultophy is not FDA-approved for fertility ("ozempic babies"); the research below reflects investigational or off-label study only.
Research on liraglutide for fertility ("ozempic babies") (9)
- Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
- The effects of liraglutide on male fertility: a case report.
- Liraglutide improved the reproductive function of obese mice by upregulating the testicular AC3/cAMP/PKA pathway.
- Modulatory effect of liraglutide on doxorubicin-induced testicular toxicity and behavioral abnormalities in rats: role of testicular-brain axis.
- Liraglutide treatment effects on rat ovarian and uterine tissues.
- Glucagon-like peptide-1 analog, liraglutide, regulates Sertoli cell energy metabolism.
- Liraglutide limits the immunogenic cell death-mediated ROS propagation and PI3K/AKT inactivation after doxorubicin-induced gonadotoxicity in rats: Involvement of the canonical Hedgehog trajectory.
- Liraglutide-Driven Weight Loss Modulates Placental Remodeling in Obese Pregnancies in Mice.
- Endometrial Transcriptome Changes following Short-Term Liraglutide Treatment in Infertile Women with Polycystic Ovarian Syndrome and Obesity.